Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8050436 | 0.87 | MEN1 (0.64) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL24884918 | 0.87 | MEN1 (0.71) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL25466799 | 0.85 | MEN1 (0.68) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL25921370 | 0.85 | MEN1 (0.68) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL25090248 | 0.85 | MEN1 (0.68) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL25466788 | 0.85 | MEN1 (0.68) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL22837715 | 0.83 | MEN1 (0.53) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL25466986 | 0.83 | MEN1 (0.59) | MEN1KMT2AALDH1A1RECQLEPHX1 | |
| SCHEMBL16384622 | 0.83 | CASP2 (0.53) | MEN1KMT2AALDH1A1PSMB5 | |
| SCHEMBL12799428 | 0.83 | MEN1 (0.78) | MEN1KMT2AALDH1A1TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | HYSLINK THERAPEUTICS (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11691982-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11535754-B2 | Silicon containing detectable compounds and uses thereof | Singular Genomics Systems, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022262789-A1 | ANTITUMOR COMPOUND AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-12-22 | — | — | WO | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| US-10815246-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2020-10-27 | — | — | US | disclosed |
| EP-3086814-B1 | DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | Bayer Pharma AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-20190233430-A1 | THAILANSTATIN ANALOGS | PH PHARMA CO., LTD. (KR) | 2019-08-01 | — | — | US | disclosed |
| US-10342882-B2 | TCO conjugates and methods for delivery of therapeutic agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20170095580-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170087258-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342882-B2 | TCO conjugates and methods for delivery of therapeutic agents | FCGR2A, PAICS, CD47 | MEN1 1382/4885KMT2A 2212/4885ALDH1A1 2533/4885 |
| US-20190233430-A1 | THAILANSTATIN ANALOGS | CD47, SUGT1, TPT1 | MEN1 2495/4885KMT2A 528/4885ALDH1A1 2912/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | MEN1 1660/4885KMT2A 2705/4885ALDH1A1 1427/4885 |
| US-10815246-B2 | Thailanstatin analogs | CD47, SUGT1, TPT1 | MEN1 2495/4885KMT2A 528/4885ALDH1A1 2912/4885 |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | KIF5B, KIF23, KIF2C | MEN1 2184/4885KMT2A 563/4885ALDH1A1 924/4885 |
| US-20170095580-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | FCGR2A, PAICS, CD47 | MEN1 1382/4885KMT2A 2212/4885ALDH1A1 2533/4885 |
| US-11691982-B2 | Thailanstatin analogs | CD47, SUGT1, TPT1 | MEN1 2495/4885KMT2A 528/4885ALDH1A1 2912/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | MEN1 2766/4885KMT2A 1237/4885ALDH1A1 4172/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | MEN1 3336/4885KMT2A 4126/4885ALDH1A1 4878/4885 |
| US-20170087258-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | FCGR2A, PAICS, CD47 | MEN1 1382/4885KMT2A 2212/4885ALDH1A1 2533/4885 |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | MEN1 1660/4885KMT2A 2705/4885ALDH1A1 1427/4885 |
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | SI, MET, MTX1 | MEN1 266/4885KMT2A 3572/4885ALDH1A1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.